BCPC

Balchem Corp

Add to Watchlist

Advanced Chart

162.090

+0.1(0.062%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

163.255

Open

162.430

VWAP

161.56

Vol

195.30K

Mkt Cap

5.26B

Low

160.890

Amount

31.55M

EV/EBITDA(TTM)

22.14

Total Shares

32.42M

5.38B

EV/OCF(TTM)

28.74

P/S(TTM)

5.38

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

258.28M

+7.64%

1.310

+15.93%

260.69M

+8.62%

1.300

+15.04%

268.40M

+7.14%

1.320

+8.2%

Estimates Revision

The market is revising No Change the revenue expectations for Balchem Corporation (BCPC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -2.46%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-2.46%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast BCPC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCPC is 189.00 USD with a low forecast of 189.00 USD and a high forecast of 189.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 162.090

Low

189.00

Averages

189.00

High

189.00

Current: 162.090

Low

189.00

Averages

189.00

High

189.00

H.C. Wainwright

Buy

maintain

$180 -> $189

2025-08-04

Reason

H.C. Wainwright

Price Target

$180 -> $189

2025-08-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Balchem to $189 from $180 and keeps a Buy rating on the shares. The company reported Q2 beat and its future growth should be driven by manufacturing expansion and anti-dumping measures, the analyst tells investors in a research note. The firm believes the European Commission's provisional anti-dumping duties on imports into the European Union of choline chloride originating in the People's Republic of China should improve the sales outlook of Balchem's choline-based products in Europe.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$190

2025-02-24

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$190

2025-02-24

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$185 → $190

2024-11-04

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$185 → $190

2024-11-04

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Balchem Corp (BCPC.O) is 30.34, compared to its 5-year average forward P/E of 33.27. For a more detailed relative valuation and DCF analysis to assess Balchem Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

33.27

Current PE

30.34

Overvalued PE

36.46

Undervalued PE

30.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

21.13

Current EV/EBITDA

19.50

Overvalued EV/EBITDA

23.12

Undervalued EV/EBITDA

19.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.89

Current PS

5.01

Overvalued PS

5.50

Undervalued PS

4.27

Financials

Annual

Quarterly

FY2025Q2

YoY :

+9.14%

255.47M

Total Revenue

FY2025Q2

YoY :

+12.33%

51.44M

Operating Profit

FY2025Q2

YoY :

+19.36%

38.28M

Net Income after Tax

FY2025Q2

YoY :

+19.39%

1.17

EPS - Diluted

FY2025Q2

YoY :

+6.10%

40.44M

Free Cash Flow

FY2025Q2

YoY :

+2.79%

36.45

Gross Profit Margin - %

FY2025Q2

YoY :

-8.70%

15.53

FCF Margin - %

FY2025Q2

YoY :

+9.34%

14.98

Net Margin - %

FY2025Q2

YoY :

+12.12%

10.73

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 2062.5% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

3.5K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

8.0K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BCPC News & Events

Events Timeline

2025-07-31 (ET)

2025-07-31

07:06:10

Balchem reports Q2 adjusted EPS $1.27 vs $1.09 last year

2025-04-24 (ET)

2025-04-24

07:05:58

Balchem reports Q1 adjusted EPS $1.22 vs $1.03 last year

2025-02-21 (ET)

2025-02-21

07:06:54

Balchem reports Q4 adjusted EPS $1.13 vs. 95c last year

News

1.0

08-26Newsfilter

Balchem Corporation to Participate in H.C. Wainwright's 27th Annual Global Investment Conference on September 9, 2025

6.5

08-18NASDAQ.COM

Analysts Predict 10% Growth Potential for FELC Holdings

5.0

08-07Yahoo Finance

Luxel Corporation Appoints Adrian Polliack, PhD, as President

People Also Watch

Civitas Resources Inc

Ingram Micro Holding Corp

Southwest Gas Holdings Inc

Cousins Properties Inc

29.490

USD

+1.03%

FAQ

What is Balchem Corp (BCPC) stock price today?

The current price of BCPC is 162.09 USD — it has increased 0.06 % in the last trading day.

BCPC

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

BCPC News & Events

Events Timeline

News

People Also Watch

FAQ

What is Balchem Corp (BCPC) stock price today?

What is Balchem Corp (BCPC)'s business?

What is the price predicton of BCPC Stock?

What is Balchem Corp (BCPC)'s revenue for the last quarter?

What is Balchem Corp (BCPC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Balchem Corp (BCPC)'s fundamentals?

How many employees does Balchem Corp (BCPC). have?

What is Balchem Corp (BCPC) market cap?